Advertisement
Recent volume and outcomes data in two major realms of cardiovascular care
Below we share recent volumes and clinical outcomes from two programs in Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute: heart failure and recovery, and electrophysiology and cardiac pacing.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Number of heart transplants, including 4 in pediatric patients and 1 heart/lung transplant
Number of left ventricular assist device (LVAD) implantations
Number of patient referrals for advanced heart failure
Time frame | Cleveland Clinic | U.S. benchmark |
---|---|---|
At 1 year | 95.9% | 91.2% |
At 3 years | 92.1% | 85.0% |
Time frame | ||
At 1 year | ||
Cleveland Clinic | ||
95.9% | ||
U.S. benchmark | ||
91.2% | ||
At 3 years | ||
Cleveland Clinic | ||
92.1% | ||
U.S. benchmark | ||
85.0% |
Number of LVAD implants over the past 3 years, among the highest volumes in the U.S. Highest-implanting center in the U.S. in 2023 (N = 83).
1-year post-implant survival, primary LVADs (vs. 87% STS Intermacs survival) (for period 4/1/22-9/30/23)
1-year post-implant survival, continuous-flow LVADs for destination therapy (vs. 84.7%% STS Intermacs survival) (for period 4/1/22-9/30/23)
Time frame | Cleveland Clinic | STS Intermacs |
---|---|---|
12 months | 85.6% | 82.7% |
48 months | 60.5% | 54.9% |
60 months | 51.8% | 46.8% |
Time frame | ||
12 months | ||
Cleveland Clinic | ||
85.6% | ||
STS Intermacs | ||
82.7% | ||
48 months | ||
Cleveland Clinic | ||
60.5% | ||
STS Intermacs | ||
54.9% | ||
60 months | ||
Cleveland Clinic | ||
51.8% | ||
STS Intermacs | ||
46.8% |
EP lab procedure volume, 2019-2023
EP lab procedure volume in 2023, highest annual total to date
Lead extraction procedures, 2019-2023
Clinical success rate for lead extractions
In-hospital mortality, vs. benchmark of 1.2% (Kusumoto et al., Heart Rhythm. 2017)
Atrial fibrillation ablations, 2019-2023
Major complication rate, vs. benchmark of 2.5% (Hsu et al., J Am Coll Cardiol. 2023)
Ventricular arrhythmia ablations, 2019-2023
Major complication rate, vs. benchmark of 10% (Cronin et al., Heart Rhythm. 2020)
Watchman™ and Amplatzer Amulet™ devices placed for LAAO procedures (inclusive of EP and interventional cases), 2019-2023
Major complication rate within 7 days of LAAO device implant, vs. benchmark of 2.7%-8.7% in published trials (Boersma et al., Eur Heart J. 2016)
Cleveland Clinic’s Heart, Vascular & Thoracic Institute has a long tradition of reporting volume and outcomes data across various subspecialty areas. For more information like the data reported above, visit clevelandclinic.org/hvtioutcomes and clevelandclinic.org/e15.
Advertisement
Advertisement
New papers review the data and provide guidance on antiobesity medications and other options
Large SURPASS registry study finds LAAO device safe and effective through one year
Metabolites from animal product substrates implicated in heart failure development in community cohorts
Large registry study explores association between statin use and long-term outcomes
Eminent clinician-researcher brings special expertise in nutritional interventions for heart failure
Sixth annual CME course takes place in Cleveland Sept. 20-21
Basic understanding of condition and treatment is lacking
Indications and issues concerning cardiac resynchronization therapy, conduction system pacing